A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Patients with superficial transitional cell carcinoma of the bladder will be treated with
intravesical suramin in a phase I dose escalating study. The toxicity of suramin
administered in this fashion will be evaluated.
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
|National Cancer Institute (NCI)||Bethesda, Maryland 20892|